ClinicalTrials.gg
CompletedNCT02006628Updated Sep 28, 2022Results posted

A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

A Phase 2 interventional study of Placebo and GWP42003 in Schizophrenia and Schizophrenia-related Psychotic Disorder, sponsored by Jazz Pharmaceuticals. Completed at 15 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing cannabidiol in Schizophrenia — none open to participants now, none under way, none of them phase 3. Cannabidiol · Schizophrenia.

Enrollment
3rd of 10
88 · median 42
Started
2014
the only one that year
Phase 2
7 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
Jazz Pharmaceuticals

Among the 10 studies testing cannabidiol in Schizophrenia, this one is the 3rd largest by enrollment, is the only one that started in 2014, is one of 7 in phase 2, and was the 4th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 10 studies testing cannabidiol in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing cannabidiol in Schizophrenia as a file.
02

Study summary

A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six weeks.

Read the detailed description

This eight-week (six-week treatment period and two-week follow-up), multi-centre, double-blind, randomized, placebo-controlled, parallel group study aimed to determine the efficacy, safety and tolerability of GWP42003 in participants with schizophrenia or a related psychotic disorder.

Eligible participants entered the study at a Screening and Randomization Visit (Day 1), where eligibility was established. Once all inclusion and exclusion criteria were reviewed, participants were randomized to receive either GWP42003 or placebo in conjunction with their prescribed anti-psychotic medications and began treatment on Day 1 as instructed. Assessments were performed on Days 8, 22, and 43. A safety follow-up visit was conducted on Day 57.

03

Conditions studied

  • Schizophrenia
  • Schizophrenia-related Psychotic Disorder

Browse trials for

Keywords

  • GWP42003
  • Cannabinoids
  • Schizophrenia
  • CBD
  • Cannabidiol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant gave written for participation in the study and did not require involuntary treatment.
  • Participant was male or female aged 18 to 65 years.
  • Participant was able (in the investigator's opinion) and willing to comply with all study requirements.
  • Participant was diagnosed with schizophrenia or a related psychotic disorder (such as schizoaffective or schizophreniform disorder) as defined by the Version 4.
  • Participant was treated for a minimum of four-weeks and was on a stable dose of his or her current anti-psychotic (AP) medication.
  • Participant showed the capacity to respond at least partially to AP medication in the opinion of the investigator.
  • Participant remained stable on his or her dose of AP and concomitant medications for the duration of the study, in the opinion of the investigator.
  • Participant was willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable in individual countries.
  • Participant was willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion criteria

Exclusion Criteria (any of the following):

  • Participant had any known or suspected to cannabinoids or any of the of the Medicinal Product (IMP).
  • Participant had a Positive and Negative Symptom Scale total score of \<60 at Day 1.
  • Participant presented with a current clinical picture and/or history that is consistent with:

    i. delirium or dementia. ii. acute drug induced psychosis. iii. bipolar disorder.

  • Participant was taking more the one AP medication during the study.
  • Female participants of child bearing potential and male participants whose partner was of child bearing potential, unless willing to ensure that they or their partner used effective , for example, oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (a male condom was not used in conjunction with a female condom).
  • Female participant who was pregnant, lactating, or planning pregnancy during the course of the study and for three months thereafter.
  • Participants who had received an IMP within 30 days prior to the screening visit.
  • Participants who had any other significant disease or disorder which, in the opinion of the investigator, either put the participant at risk because of participation in the study, or may have influenced the result of the study, or the participant's ability to participate in the study.
  • Participant had any abnormalities following a physical examination that, in the opinion of the investigator, prevented the participant from safe participation in the study.
  • Participant was unwilling to abstain from donation of blood during the study.
  • Participant had travelled outside the country of residence during the study.
  • Participant previously randomized into this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    GWP42003 1000 milligrams (mg)/day

    Participants received GWP42003 (100 mg/milliliter \[mL\]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.

    Drug: GWP42003

  • Placebo comparator
    Placebo

    Participants received placebo (0 mL cannabidiol \[CBD\]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.

    Also known as: Placebo control

  • GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.

    Also known as: Cannabidiol

06

What researchers measure

Primary outcomes

  1. Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score

    The PANSS was a 30-item medical scale completed by a trained rater that assessed the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. The PANSS Total score was derived from the sum of the 30 items, which were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total score is the summed total for each of the PANSS positive symptom ('P'), negative symptom ('N'), general psychopathology symptom ('G') scores and could range from 30 to 210 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  2. Percentage Of PANSS Total Score Responders At End Of Treatment (Day 43)

    The percentage of PANSS treatment responders, defined as participants with ≥20% improvement in PANSS Total score between baseline and End of Treatment, is presented. The percentage of participants was calculated by dividing the number of participants with a ≥20% improvement in PANSS Total score (yes) by the total number of participants.

    Time frame: Day 1 through Day 43

  3. Change From Baseline To The End Of Treatment (Day 43) In PANSS 'P' Score

    The PANSS 'P' scale measured the severity of positive symptoms, including delusions, conceptual disorganization, hallucinations, hyperactivity, grandiosity, suspiciousness/persecution, and hostility. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'P' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  4. Change From Baseline To The End Of Treatment (Day 43) In PANSS 'N' Score

    The PANSS 'N' scale measured the severity of negative symptoms, including blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'N' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  5. Change From Baseline To The End Of Treatment (Day 43) In PANSS 'G' Score

    The PANSS 'G' scale measured the severity of general psychopathology symptoms, including somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgement and insight, disturbance of violation, poor impulse control, preoccupation, and active social avoidance. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'G' score could range from 16 to 112 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  6. Change From Baseline To The End Of Treatment (Day 43) In The Scale For The Assessment Of Negative Symptoms (SANS)

    The SANS assessed 5 symptom complexes to obtain clinical ratings of negative symptoms in participants with schizophrenia or related psychotic disorder. Symptom complexes were affective blunting, alogia (impoverished thinking), avolition/apathy, anhedonia/asociality, and disturbance of attention. Assessments were conducted on a 6-point scale (0 = not at all; 5 = severe). The total score could range from 0 to 125 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  7. Change From Baseline To The End Of Treatment (Day 43) In The Clinical Global Impression Severity Scale (CGI-S)

    The CGI-S was a 7-point scale that required the clinician to rate the severity of a participant's illness at the time of assessment, relative to the clinician's past experience of participants who had the same diagnosis. Considering total clinical experience, participants were assessed on severity of mental illness at the time of rating on the following scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Lower scores equated to milder severity of symptoms, that is, closer to psychologically normal.

    Time frame: Day 1 through Day 43

  8. Clinical Global Impression Improvement Scale (CGI-I) Values At Day 8 And End Of Treatment (Day 43)

    The CGI-I was a 7-point scale that required the clinician to assess how much a participant's illness had improved or worsened relative the first assessment at the beginning of the intervention. This was rated on the following scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Lower scores equated to improvement of symptoms.

    Time frame: Day 8 through Day 43

  9. Change From Baseline To The End Of Treatment (Day 43) In Brief Assessment Of Cognition In Schizophrenia (BACS) Score

    The BACS was an instrument used to assess the aspects of cognition found to be most impaired and most strongly correlated with outcome in participants with schizophrenia or related psychotic disorder. The BACS consisted of 6 domains: verbal memory (score range 0 to 75), working memory (score range 0 to 28), motor speed (score range 0 to 100), verbal fluency (score \> 0, with no set maximum value), attention and speed of information processing (score range 0 to 110), and executive functions (score range 0 to 22). A score was obtained for each of the 6 domains. A composite summary score was then calculated as the arithmetic mean of the unweighted scores from the 6 domains. While there was not an upper limit on the composite score, overall, an increase in score was indicative of an improvement in cognition.

    Time frame: Day 1 through Day 43

07

Results

Posted Jul 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneGWP42003 1000 Milligram (mg)/DayPlacebo
Started4345
Received at least 1 dose of study drug4345
Intention to treat (itt) analysis set4244
Completed4043
Not completed32
Withdrew: Adverse event11
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryChange From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score

The PANSS was a 30-item medical scale completed by a trained rater that assessed the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. The PANSS Total score was derived from the sum of the 30 items, which were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total score is the summed total for each of the PANSS positive symptom ('P'), negative symptom ('N'), general psychopathology symptom ('G') scores and could range from 30 to 210 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score79.3 ± 12.4580.6 ± 14.90
End of Treatment score68.1 ± 14.7971.9 ± 15.49
Change from baseline-11.2 ± 7.87-8.8 ± 8.87
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.1332 · Treatment difference (gwp42003-placebo): -2.8 · 95% CI -6.5 to 0.9Change from baseline as the response variable, treatment as fixed effect, and individual baseline subscore and age as covariates.
PrimaryPercentage Of PANSS Total Score Responders At End Of Treatment (Day 43)

The percentage of PANSS treatment responders, defined as participants with ≥20% improvement in PANSS Total score between baseline and End of Treatment, is presented. The percentage of participants was calculated by dividing the number of participants with a ≥20% improvement in PANSS Total score (yes) by the total number of participants.

Time frame:
Day 1 through Day 43
Reported as:
Count of participants · Participants
Percentage Of PANSS Total Score Responders At End Of Treatment (Day 43)
ParticipantsGWP42003 1000 mg/DayPlacebo
Yes126
No3038
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · Regression, Logistic · p = 0.0896 · Odds ratio (or): 2.62 · 95% CI 0.86 to 8.00Responder (yes/no) is the dependent variable with treatment included as factor and age and baseline P, G, and N scores included as covariates.
PrimaryChange From Baseline To The End Of Treatment (Day 43) In PANSS 'P' Score

The PANSS 'P' scale measured the severity of positive symptoms, including delusions, conceptual disorganization, hallucinations, hyperactivity, grandiosity, suspiciousness/persecution, and hostility. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'P' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In PANSS 'P' Score
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score18.0 ± 3.8917.5 ± 3.29
End of Treatment score14.8 ± 4.0115.7 ± 3.73
Change from Baseline-3.2 ± 2.60-1.7 ± 2.76
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.0188 · Treatment difference (gwp42003-placebo): -1.4 · 95% CI -2.5 to -0.2
PrimaryChange From Baseline To The End Of Treatment (Day 43) In PANSS 'N' Score

The PANSS 'N' scale measured the severity of negative symptoms, including blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'N' score could range from 7 to 49 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In PANSS 'N' Score
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score22.6 ± 5.0423.4 ± 5.11
End of Treatment score19.9 ± 5.3220.5 ± 5.22
Change from Baseline-2.7 ± 3.55-2.9 ± 3.06
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.9647 · Treatment difference (gwp42003-placebo): 0.0 · 95% CI -1.3 to 1.4
PrimaryChange From Baseline To The End Of Treatment (Day 43) In PANSS 'G' Score

The PANSS 'G' scale measured the severity of general psychopathology symptoms, including somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgement and insight, disturbance of violation, poor impulse control, preoccupation, and active social avoidance. Individual items were rated on a 7-point scale, where 1 = absent and 7 = extreme. The total 'G' score could range from 16 to 112 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In PANSS 'G' Score
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score38.7 ± 6.7139.7 ± 8.95
End of Treatment score33.4 ± 7.6935.6 ± 9.04
Change from Baseline-5.3 ± 4.34-4.1 ± 4.78
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.1963 · Treatment difference (gwp42003-placebo): -1.3 · 95% CI -3.2 to 0.7
PrimaryChange From Baseline To The End Of Treatment (Day 43) In The Scale For The Assessment Of Negative Symptoms (SANS)

The SANS assessed 5 symptom complexes to obtain clinical ratings of negative symptoms in participants with schizophrenia or related psychotic disorder. Symptom complexes were affective blunting, alogia (impoverished thinking), avolition/apathy, anhedonia/asociality, and disturbance of attention. Assessments were conducted on a 6-point scale (0 = not at all; 5 = severe). The total score could range from 0 to 125 points, with lower scores equating to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In The Scale For The Assessment Of Negative Symptoms (SANS)
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score52.8 ± 17.1055.3 ± 16.24
End of Treatment score43.6 ± 16.5448.4 ± 15.75
Change from Baseline-9.1 ± 13.09-6.3 ± 8.54
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.1167 · Treatment difference (gwp42003-placebo): -3.5 · 95% CI -7.9 to 0.9
PrimaryChange From Baseline To The End Of Treatment (Day 43) In The Clinical Global Impression Severity Scale (CGI-S)

The CGI-S was a 7-point scale that required the clinician to rate the severity of a participant's illness at the time of assessment, relative to the clinician's past experience of participants who had the same diagnosis. Considering total clinical experience, participants were assessed on severity of mental illness at the time of rating on the following scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Lower scores equated to milder severity of symptoms, that is, closer to psychologically normal.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In The Clinical Global Impression Severity Scale (CGI-S)
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score4.0 ± 0.704.0 ± 0.65
End of Treatment score3.5 ± 1.093.8 ± 0.78
Change from Baseline-0.5 ± 0.74-0.3 ± 0.49
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.0443 · Treatment difference (gwp42003-placebo): -0.3 · 95% CI -0.5 to 0.0
PrimaryClinical Global Impression Improvement Scale (CGI-I) Values At Day 8 And End Of Treatment (Day 43)

The CGI-I was a 7-point scale that required the clinician to assess how much a participant's illness had improved or worsened relative the first assessment at the beginning of the intervention. This was rated on the following scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Lower scores equated to improvement of symptoms.

Time frame:
Day 8 through Day 43
Reported as:
Mean · score on a scale
Clinical Global Impression Improvement Scale (CGI-I) Values At Day 8 And End Of Treatment (Day 43)
score on a scaleGWP42003 1000 mg/DayPlacebo
Day 8 score3.6 ± 0.503.8 ± 0.56
End of Treatment score2.9 ± 0.893.4 ± 0.87
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.0182 · Treatment difference (gwp42003-placebo): -0.5 · 95% CI -0.8 to -0.1
PrimaryChange From Baseline To The End Of Treatment (Day 43) In Brief Assessment Of Cognition In Schizophrenia (BACS) Score

The BACS was an instrument used to assess the aspects of cognition found to be most impaired and most strongly correlated with outcome in participants with schizophrenia or related psychotic disorder. The BACS consisted of 6 domains: verbal memory (score range 0 to 75), working memory (score range 0 to 28), motor speed (score range 0 to 100), verbal fluency (score \> 0, with no set maximum value), attention and speed of information processing (score range 0 to 110), and executive functions (score range 0 to 22). A score was obtained for each of the 6 domains. A composite summary score was then calculated as the arithmetic mean of the unweighted scores from the 6 domains. While there was not an upper limit on the composite score, overall, an increase in score was indicative of an improvement in cognition.

Time frame:
Day 1 through Day 43
Reported as:
Mean · score on a scale
Change From Baseline To The End Of Treatment (Day 43) In Brief Assessment Of Cognition In Schizophrenia (BACS) Score
score on a scaleGWP42003 1000 mg/DayPlacebo
Baseline score32.21 ± 6.04232.91 ± 7.158
End of Treatment score35.73 ± 6.98135.05 ± 7.310
Change from Baseline3.48 ± 3.0312.14 ± 3.442
Statistical analysis
  • GWP42003 1000 mg/Day vs Placebo · ANCOVA · p = 0.0677 · Treatment difference (gwp42003-placebo): 1.31 · 95% CI -0.10 to 2.72

Adverse events

Collected over Day 1 through Day 57. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003 1000 mg/Day—0/43 (0%)8/43 (18.6%)
Placebo—1/45 (2.2%)10/45 (22.2%)
Most frequent serious events
Most frequent serious events
EventGWP42003 1000 mg/DayPlacebo
SchizophreniaPsychiatric disorders0/431/45
Most frequent other events
Most frequent other events
EventGWP42003 1000 mg/DayPlacebo
DiarrhoeaGastrointestinal disorders4/432/45
HeadacheNervous system disorders3/434/45
NauseaGastrointestinal disorders3/430/45
SomnolenceNervous system disorders0/433/45
InsomniaPsychiatric disorders0/432/45

Baseline characteristics

Safety analysis set: Participants who provided informed consent, were randomized to 1 of the treatment groups, and took at least 1 dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)GWP42003 1000 mg/DayPlaceboTotal
Mean40.9 ± 12.4940.8 ± 11.0040.8 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003 1000 mg/DayPlaceboTotal
Female152237
Male282351
08

Study locations

15 sites
  • Czeladź, 41-250, Poland
  • Gdansk, 80-952, Poland
  • Kielce, 25-103, Poland
  • Lublin, 20-831, Poland
  • Tychy, 43-100, Poland
  • Wrocław, 54-235, Poland
  • Bucharest, 041914, Romania
  • Bucuresti, 010825, Romania
  • Bucuresti, 041914, Romania
  • Sibiu, 550082, Romania
  • Targoviste, 130086, Romania
  • Târgu-Mureş, 540096, Romania
  • Chertsey, KT16 0AE, United Kingdom
  • Coventry, CV2 2TE, United Kingdom
  • London, SE5 8AF, United Kingdom
09

References and documents

Publications

  • McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. PubMed 29241357 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Jan 2015, 10 months.

Results were first posted in Jul 2019, 4 years 6 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 10 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
StartActual
Feb 25, 2014
Primary completionActual
Jan 8, 2015
CompletionActual
Jan 8, 2015
Results first posted
Jul 26, 2019
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02006628
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Feb 25, 2014
Primary completion
Jan 8, 2015
Completion
Jan 8, 2015
Results posted
Jul 26, 2019
Last update
Sep 28, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion